Search Results - "Gul, Engin"

The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database by Cherniawsky, Hannah M., Kukreti, Vishal, Reece, Donna, Masih-Khan, Esther, McCurdy, Arleigh, Jimenez-Zepeda, Victor H., Sebag, Michael, Song, Kevin, White, Darrell, Stakiw, Julie, LeBlanc, Richard, Reiman, Anthony, Aslam, Muhammad, Louzada, Martha, Kotb, Rami, Gul, Engin, Atenafu, Eshetu, Venner, Christopher P.

Get full text

Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial by McCurdy, Arleigh, Reece, Donna, Louzada, Martha L., White, Darrell, Parkin, Stephen, Chu, Michael P., Kotb, Rami, Mian, Hira, Othman, Ibraheem, Su, Jiandong, Khan, Aniba, Gul, Engin, Trudel, Suzanne

“…Given the early use of triplet and quadruplet regimens, most patients with multiple myeloma (MM) will be exposed and/or refractory to PIs, IMiDs, and anti-CD38…”
Get full text

Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis by McCurdy, Arleigh, Mian, Hira, LeBlanc, Richard, Jimenez-Zepeda, Victor H., Su, Jiandong, Masih-Khan, Esther, Visram, Alissa, Louzada, Martha, Song, Kevin, White, Darrell, Sebag, Michael, Stakiw, Julie, Reiman, Anthony, Aslam, Muhammad, Bergstrom, Debra, Kotb, Rami, Kaedbey, Rayan, Gul, Engin, Reece, Donna, Venner, Christopher P.

“…While most patients diagnosed with multiple myeloma (MM) receive initial therapy, reported attrition rates are high. Understanding attrition rates and…”
Get full text

Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database by Côté, Julie, LeBlanc, Richard, Mian, Hira, Chu, Michael P., McCurdy, Arleigh, Masih-Khan, Esther, Su, Jiandong, Jimenez-Zepeda, Victor H., Song, Kevin, Louzada, Martha, White, Darrell, Sebag, Michael, Reiman, Anthony, Stakiw, Julie, Kotb, Rami, Bergstrom, Debra, Aslam, Muhammad, Kaedbey, Rayan, Venner, Christopher P., Gul, Engin, Reece, Donna

“…Autologous stem cell transplant (ASCT) remains an important option for eligible multiple myeloma (MM) patients as part of initial therapy. Using the Canadian…”
Get full text

Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database Study by Tanguay, Mégane, Roy, Jean, Su, Jiandong, Gul, Engin, Reece, Donna, Venner, Christopher P., White, Darrell, Chu, Michael P., Jimenez‐Zepada, Victor H., Song, Kevin, Mccurdy, Arleigh, Mian, Hira, Sebag, Michael, Bergstrom, Debra, Stakiw, Julie, Reiman, Anthony, Kotb, Rami, Aslam, Muhammad, Kaedbey, Rayan, Louzada, Martha, LeBlanc, Richard

“…ABSTRACT Background Young patients ≤ 50 years old with multiple myeloma (MM) account for about 10% of cases and are underrepresented in the literature. Methods…”
Get full text

Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database by McCurdy, Arleigh, Venner, Christopher P, Masih-Khan, Esther, Louzada, Martha, LeBlanc, Richard, Sebag, Michael, Song, Kevin, Jimenez-Zepeda, Victor H, Kotb, Rami, Kardjadj, Moustafa, Mian, Hira, White, Darrell, Stakiw, Julie, Aslam, Muhammad, Reiman, Anthony, Gul, Engin, Reece, Donna

“…The treatment of multiple myeloma has dramatically improved due to the availability of novel therapies that are highly effective and are quickly moving into…”
Get full text

Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis by McCurdy, Arleigh, Mian, Hira, LeBlanc, Richard, Jimenez-Zepeda, Victor H., Su, Jiandong, Masih-Khan, Esther, Visram, Alissa, Louzada, Martha, Song, Kevin, White, Darrell, Sebag, Michael, Stakiw, Julie, Reiman, Anthony, Aslam, Muhammad, Bergstrom, Debra, Kotb, Rami, Kaedbey, Rayan, Gul, Engin, Reece, Donna, Venner, Christopher P.

Get full text

Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis by Mian, Hira, Eisfeld, Christine, Venner, Christopher P, Masih-Khan, Esther, Kardjadj, Moustafa, Jimenez-Zepeda, Victor H, Khandanpour, Cyrus, Lenz, Georg, McCurdy, Arleigh, Sebag, Michael, Song, Kevin, LeBlanc, Richard, White, Darrell, Stakiw, Julie, Reiman, Anthony, Louzada, Martha, Aslam, Muhammad, Kotb, Rami, Gul, Engin, Reece, Donna

“…Daratumumab, a monoclonal antibody directed against CD38 is a recent class of drugs introduced into the multiple myeloma therapeutic landscape. While clinical…”
Get full text

Long‐term follow‐up of outcomes including progression‐free survival 2 in patients with transplant‐ineligible multiple myeloma in the real‐world practice: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) database by Kaedbey, Rayan, Reece, Donna, Venner, Christopher P., McCurdy, Arleigh, Su, Jiandong, Chu, Michael, Louzada, Martha, Jimenez‐Zepeda, Victor H, Mian, Hira, Song, Kevin, Sebag, Michael, Stakiw, Julie, White, Darrell, Reiman, Anthony, Aslam, Muhammad, Kotb, Rami, Bergstrom, Debra, Gul, Engin, LeBlanc, Richard

“…Multiple myeloma remains an incurable cancer mostly affecting older adults and is characterized by a series of remission inductions and relapses. This study…”
Get full text

Real‐world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database by Mian, Hira, LeBlanc, Richard, Louzada, Martha, Masih‐Khan, Esther, McCurdy, Arleigh, Venner, Christopher P., Stakiw, Julie, Kardjadj, Moustafa, Jimenez‐Zepeda, Victor H., Sebag, Michael, White, Darrell, Aslam, Muhammad, Song, Kevin, Reiman, Anthony, Kotb, Rami, Gul, Engin, Reece, Donna

“…Using the Canadian Myeloma Research Group Database, a retrospective study of 167 newly diagnosed, transplant‐ineligible patients with multiple myeloma (MM)…”
Get full text

Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) Database by McCurdy, Arleigh, Louzada, Martha, Venner, Christopher P., Visram, Alissa, Masih‐Khan, Esther, Kardjadj, Moustafa, Jimenez‐Zepeda, Victor H., LeBlanc, Richard, Sebag, Michael, Song, Kevin, White, Darrell, Mian, Hira, Stakiw, Julie, Reiman, Anthony, Aslam, Muhammad, Kotb, Rami, Gul, Engin, Reece, Donna

“…Carfilzomib is an active and commonly used treatment in patients with multiple myeloma (MM). Using the Canadian Myeloma Research Group Database, we performed a…”
Get full text

A Phase 2 Multi-Center, Open Label Study of Isatuximab Added to Standard Cybord Induction and Lenalidomide Maintenance Treatments in Newly Diagnosed, Transplant Eligible Multiple Myeloma by Kotb, Rami, Gul, Engin, Reece, Donna E.

“…Background: Despite recent improvements, myeloma is still incurable. There is need to add new therapeutic tools. For young and fit patients, the current…”
Get full text

CD4 + T Cells of Myasthenia Gravis Patients Are Characterized by Increased IL-21, IL-4, and IL-17A Productions and Higher Presence of PD-1 and ICOS by Çebi, Merve, Durmus, Hacer, Aysal, Fikret, Özkan, Berker, Gül, Gizem Engin, Çakar, Arman, Hocaoglu, Mehmet, Mercan, Metin, Yentür, Sibel P, Tütüncü, Melih, Yayla, Vildan, Akan, Onur, Dogan, Öner, Parman, Yeşim, Saruhan-Direskeneli, Güher

“…Myasthenia gravis (MG) is an autoimmune disease mediated by autoantibodies predominantly against the acetylcholine receptor (AChR). Specific T cell subsets are…”
Get full text

Pembrolizumab Added to First-Line Cyclophosphamide, Bortezomib and Dexamethasone in Newly Diagnosed Transplant Non-Eligible Myeloma Patients: A Phase 2A Open Label, Multi Centre Study by Kotb, Rami, Gul, Engin, Abdel-Samad, Nizar, Othman, Ibraheem, Pavic, Michel, Reece, Donna E.

“…Background: Despite recent improvements, myeloma is still incurable. There is need to add new therapeutic tools. The combination of the proteasome inhibitor…”
Get full text

Efficacy and Tolerance of Isatuximab, Cyclophosphamide, Bortezomib, and Dexamethasone (Isa-CBD) Induction Chemotherapy in Newly Diagnosed, Transplant Eligible Multiple Myeloma: Report of the Phase 2 Multi-Centre, Open Label Canadian Myeloma Research Group (CMRG)-008 Prospective Clinical Trial by Kotb, Rami, White, Darrell, Bhella, Sita, McCurdy, Arleigh, Sandhu, Irwindeep, Mian, Hira, Stakiw, Julie, Othman, Ibraheem, Su, Jiandong, Khan, Aniba, Gul, Engin, Reece, Donna

“…Background: The previous standard Canadian approach to autologous stem cell transplantation (ASCT) included CyBorD induction and single-agent lenalidomide…”
Get full text

Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial by Trudel, Suzanne, McCurdy, Arleigh, Louzada, Martha L., Parkin, Stephen, White, Darrell, Chu, Michael P., Kotb, Rami, Mian, Hira, Othman, Ibraheem, Su, Jiandong, Khan, Aniba, Gul, Engin, Reece, Donna

“…Due to evolving treatment standards for newly diagnosed multiple myeloma, many patients will be triple-class exposed after initial relapses and have poor…”
Get full text

Prevention of Ocular Toxicity Using Protective Contact Lenses in Multiple Myeloma Patients Receiving Belantamab Mafodotin, Pomalidomide and Dexamethasone: A Sub-Study of the Cmrg-007 Trial by Louzada, Martha L, Reece, Donna E., McCurdy, Arleigh, Kotb, Rami, Othman, Ibraheem, Mian, Hira, Lin, Toni, Chu, Michael P, White, Darrell, Parkin, Stephen, Gul, Engin, Khan, Aniba, Trudel, Suzanne

“…Background: Belantamab mafodotin (belamaf) is a monomethyl auristatin-F containing antibody drug conjugate that targets BMCA on myeloma cells. Single agent…”
Get full text

A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab Versus Physician's Choice of Treatment Among Patients with Triple-Class Exposed/Refractory Multiple Myeloma in Canada by Mol, Isha, Hu, Yannan, Fanton-Aita, Fiorella, On, Phu Vinh, Gonzalez, Hicham, LeBlanc, Richard, Reece, Donna, Su, Jiandong, Gul, Engin, Visram, Alissa, Cappelleri, Joseph C, Chu, Haitao, Nador, Guido, Hlavacek, Patrick

“…BACKGROUND Given the poor prognosis and limited treatment options for patients with triple-class exposed/refractory multiple myeloma (TCE/R MM), there is a…”
Get full text

Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma by Trudel, Suzanne, McCurdy, Arleigh, Fu, Molei, Sutherland, Heather J., Louzada, Martha L, Chu, Michael P., White, Darrell J, Mian, Hira S, Kotb, Rami, Othman, Ibraheem, Kardjadj, Moustafa, Gul, Engin, Reece, Donna E.

Get full text

A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma by Khan, Sahar, LeBlanc, Richard, Gyger, Martin, White, Darrell, Kaufman, Johnathan, Jazubowiak, Andrzej, Gul, Engin, Paul, Harminder, Le, Lisa W., Lau, Anthea, Li, Zhihua, Trudel, Suzanne

“…We report results of a phase-1 study evaluating the safety and anti-cancer activity of the small molecule insulin-like growth factor-1 receptor (IGF-1R)…”
Get full text